Incyte Genomics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
biotech analyst at Jefferies. We are here in London at the Jefferies Global Healthcare Conference. Thank you all for joining. Really pleased to have with us today the management team of Incyte. We have Bill Meury, Dave Gardner with me on stage. We have a ton to get through, and I am looking at the timer already ticking down. Bill, why don't you kick it off, give us some opening remarks?
Great. We are through the end of 2026. I think we are in a much stronger position today than we were at the beginning of 2026. We think about running the company on two dimensions. First, we have a core business ex-JAKAFI, which is solidly on track by 2030 to reach about $3 billion-$4 billion. That is important because it creates a foundation for Incyte. Then we have a pipeline of phase III assets that today are increasingly de-risked, and what we are focused on is phase III study execution. I think when we look at the pipeline, there are four assets that, on a risk-adjusted basis, could create a great deal of value for the company. That is, of course, povorcitinib, which is under review at the FDA. We have INCA033989, our CALR antibody for MF and ET.
We have our G12D inhibitor for pancreatic cancer, and latarcibart, which is a Protein S modulator for von Willebrand. I think they are high PTS projects and have the potential, on an unadjusted basis, to 2X the company over the long term. The last point I would make is we have an outlier opportunity in TGF-beta by PD-1 for colorectal cancer. We shared data at ESMO several weeks ago on top of FOLFOX/Bev standard of care. Response rates in the all-comers population, PD-L1 positive, and in patients with liver mets was impressive. But the battleground there is PFS, and we will get data throughout 2027 on that program. On an unadjusted basis, that product could be the largest one we have, but we have to make sure the response rate holds up.
Right now, the job is just to continue to execute on the two dimensions of the company that I talked about.
Got it. Awesome, Bill. Bill, I really like the situation that you're working yourself through, almost on an intellectual basis. It's like biotech circle of life, right? Incyte has had great success with JAKAFI. Now you're trying to reinvent for kind of the next generation. We got to talk about G12D, we got to talk about CALR, and with Dave here, I want to talk about BD as well. Bill, why don't you decide which one you want to talk about first?
Well, let's start with, since ASH is approaching, I think we can start with INCA033989.
Got it. Yeah, so let's break it down. Can you talk about kind of what you've shown so far with INCA033989, where you're at on pivotal study initiation, and then we can talk about expectations for ASH?
Yeah, so right now, we have a second-line ET study that's being run and a second-line MF study with INCA033989 on conventional endpoints of SVR35, TSS50, and anemia response. We are getting ready by the middle of 2027 to start a frontline study. Here's what we know right now about the antibody. We know what the benchmarks are in the second-line setting on conventional endpoints, and we know what the benchmarks are in the frontline setting for MF. INCA033989 has cleared, in our opinion, all the benchmarks in the second-line MF setting. Now, in the frontline setting, we'll share data at ASH in several weeks. What we've always said is that if we can replicate the data that we showed at EHA in a JAK-ineligible population at ASH, we believe we have a strong competitive profile and a line of sight to a successful frontline study.
I think you'll find the results on conventional endpoints, SVR35, TSS50, and anemia response, as very, very encouraging. It'll be a function of a discussion with the FDA about whether we design a monotherapy or a monotherapy and combination study. I think the use case for INCA033989 as mono and combo therapy is very relevant. I think there's likelihood that we could have a three-arm study, and you'll be able to see what we see at ASH, but I'm very encouraged about where that program is right now.
Got it. Can you just talk about the nuances around getting a composite endpoint? What does a composite endpoint mean from a biology basis, the differences between what the two drugs are doing? Why is a composite endpoint potentially beneficial here?
Yeah, it's a really good question. If we were developing another pathway blocker, another JAK inhibitor, or another mechanism, SVR35 and TSS50 could make a great deal of sense. It's symptomatic therapy. But INCA033989 is an antibody targeting the driver mutation, CALR, and we believe that we should look at a range of disease dimensions. In hematology and in the treatment of MF, that includes spleen volume, hemoglobin, platelets, and blast counts. As a base case, we assume that we're going to be using conventional endpoints in our phase III study. I think that's the prudent thing to do. But we will have a conversation with the agency at the beginning of 2027 to talk about measuring a targeted treatment differently than a pathway blocker. If the FDA prefers the conventional endpoints, we will use the composite endpoint as a powered key secondary endpoint.
Got it. Can you break down sort of, maybe from the agency's perspective as you see it, what are the pros and cons between allowing or disallowing a composite endpoint? Because hearing you talk about this concept, right, like in MF, it's spleen volume and it's TSS. Only one of those is an objective endpoint. When you talk about composite, you're actually talking about objective measures. So, I'm kind of surprised that you're still saying like base case is spleen volume and TSS.
Yeah, I think it's an administrative step in changing an endpoint. While there are precedents at the FDA, it takes a little bit of work. What the FDA looks for, as many of you may know, you either have to make people feel better or make them live longer. What they're going to look at is correlation between the individual components of this composite and ultimately outcomes. We, of course, have data and modeling that we'll share with the division. This will be the first conversation we've had with the agency about changing the endpoint, and we'll provide some sort of an update in the middle of 2027.
Got it. Bill, can I just ask you to clarify that? Because I believe in second-line MF, you guys had at least thought about or considered moving to a composite endpoint. Can you just remind us where did those conversations land and what's different happening here?
Yeah. We talked to the review division about a new endpoint, and of course, the review division said, "You'll need to talk to the surrogate endpoints division." That's really procedural, and we did not want to wait to start the second-line MF study. That's why we started the study and used the composite, as I said, as a powered key secondary endpoint. For the frontline study, we have two options here, and it'll be determined when we finish our conversations with the FDA.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
